In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Trevena (TRVN – Research Report), with a price target of $2.00. The company’s shares opened today at $0.85.
According to TipRanks, Butler is an analyst with an average return of -7.1% and a 39.72% success rate. Butler covers the Healthcare sector, focusing on stocks such as Cormedix, Cytokinetics, and Esperion.
Trevena has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $12.20 and a one-year low of $0.58. Currently, Trevena has an average volume of 104.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trevena, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
Read More on TRVN:
- Trevena Announces Approval of OLINVYK in China
- Trevena to Participate in Three Upcoming Conferences
- Trevena price target lowered to $9 from $11 at H.C. Wainwright
- Trevena announces OLINVYK data from real-world clinical outcomes study
- Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
